In early September 2025, Veronika Skvortsova, head of Russia’s Federal Medical and Biological Agency (FMBA), announced a breakthrough.
The Enteromix cancer vaccine had completed preclinical trials. The results showed strong safety and effectiveness. Authorities called the vaccine “ready for clinical use.”
Enteromix is a personalized mRNA-based vaccine. It trains the immune system to recognize and attack cancer cells. The vaccine combines messenger RNA technology with harmless viruses. This approach targets tumors while reducing side effects.
After the announcement, Russian authorities submitted regulatory documents to the Ministry of Health. If approved, Enteromix could become a major step forward in cancer treatment in Russia.
The vaccine’s development shows Russia’s focus on innovative medical solutions. It uses mRNA technology, the same platform as some COVID-19 vaccines. Officials plan to make the vaccine available to patients, especially those whose cancers do not respond to standard treatments.
Experts remain cautious. They say larger clinical trials are to confirm safety and effectiveness in humans. The next months will be crucial as Enteromix moves from preclinical success to formal approval and clinical use.
Also read: President Ruto Backs Ethiopia Power Deal
